Trans-sodium crocetinate

Drug Profile

Trans-sodium crocetinate

Alternative Names: Sodium crocetinate; Transcrocetinate sodium; TSC

Latest Information Update: 26 Apr 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator University of Virginia
  • Developer Diffusion Pharmaceuticals
  • Class Antineoplastics; Carotenoids; Radiation-sensitising agents; Small molecules; Vascular disorder therapies
  • Mechanism of Action Oxygen compound modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Glioblastoma; Brain metastases
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase I/II Glioblastoma
  • Preclinical Brain metastases; Pancreatic cancer
  • No development reported Peripheral arterial disorders

Most Recent Events

  • 17 Oct 2017 Diffusion Pharmaceuticals plans a phase III trial for Glioblastoma (Combination therapy, Newly diagnosed) in USA and EU by the end of 2017
  • 31 Mar 2017 Diffusion Pharmaceuticals has patent pending for product candidates including TSC in World
  • 31 Mar 2017 Diffusion Pharmaceuticals has patent protection for product candidates including TSC in China, Europe, India, Japan and USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top